QIAGEN

68 articles with QIAGEN

• QIAGEN Forms Strategic Alliance With Sysmex Corporation for Global Cancer Companion Diagnostics Development and Commercialization Using NGS and Plasma-Safe-SeqS Technology

  7/1/2021

  QIAGEN announced a global strategic alliance with Japan’s Sysmex Corporation for the development and commercialization of cancer companion diagnostics, which will leverage both QIAGEN’s leadership in this field and Sysmex’s Plasma-Safe-SeqS technology for next generation sequencing.

• Statement from Davidson Kempner regarding Qiagen

  6/30/2021

  Qiagen's Supervisory Board suffers from a lack of trust and confidence due to its history of ineffectiveness and governance concerns. This has created a credibility issue that is currently reflected in Qiagen's steep valuation discount to peers and its own historic multiples, and negatively impacts the business.

• 

  QIAGEN Partners with Verogen to Bolster Forensics Field

  6/30/2021

  The two companies will collaborate to market Verogen’s forensically validated NGS workflows alongside QIAGEN’s full range of forensic-grade chemistries and sample prep automation.

• QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments

  6/21/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions that allow researchers to analyze edited genetic material with unparalleled speed and efficiency to determine how their interventions have changed the function of the DNA sequence in question.

• QIAGEN Launches artus Prep as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity

  4/20/2021

  QIAGEN’s innovative technology integrates sample preparation and detection in a single kit, enabling throughput of more than 670 tests per PCR cycler in an eight-hour shift

• Abcam and MEDx extend precision medicine strategic partnership

  4/12/2021

  Abcam, a global innovator in life science reagents and tools, and MEDx Translational Medicine, formerly QIAGEN Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market.

• QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance

  4/6/2021

  QIAseq DIRECT SARS-CoV-2 Kit halves both library preparation times and plasticware use Kit supports analysis of over 6,000 samples simultaneously on highest-throughput sequencers Integrates with QIAGEN Digital Insights cloud solutions to support variant detection and reporting including clade and lineage annotations across sequencing platforms

• QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

  3/3/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.

• QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia

  2/24/2021

  Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions

• INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

  2/24/2021

  Liquid biopsy-based precision test guides patient selection and offers potential for cost-effective, non-invasive alternative to surgical removal of cervical lesions

• QIAGEN Expands Supervisory Board With Appointment of a New Member

  2/22/2021

  QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today the appointment of Thomas Ebeling, a leading international executive with extensive experience in the healthcare, media and consumer goods industries, as a member of the Supervisory Board with immediate effect.

• QIAGEN Adds dPCR Platform QIAcuity to Growing Portfolio of COVID-19 Testing Solutions for Wastewater and Mutation Testing

  1/28/2021

  Digital PCR for COVID-19 wastewater testing overcomes limitations of traditional PCR Wastewater surveillance testing can quantify COVID-19 in populations and track mutations Custom QIAcuity One-Step Viral RT-PCR Kit supports wastewater testing applications

• QIAGEN Plans to Resubmit EUA Submission in the U.S. for QIAreach SARS-CoV-2 Antigen Test in the First Quarter of 2021

  1/20/2021

  QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 antigens in people with active infections in 15 minutes.

• QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus

  1/20/2021

  QIAGEN Confirms Effectiveness of Its SARS-CoV-2 PCR Tests in the Face of Mutations of the Coronavirus QIAstat-Dx and NeuMoDx tests continue to detect all known viral variants extremely effectively

• QIAGEN Adopts GNS Healthcare's Gemini - The in silico Patient™ Across Multiple Cancers

  1/19/2021

  Partnership enables enhanced capability to discover new targets and prognostic markers

• Personal Genome Diagnostics and QIAGEN Collaborate to Offer Integrated Genomic Testing and Interpretation Support

  1/13/2021

  Partnership to Accelerate Adoption of Next-Generation Sequencing (NGS) in Clinical Decision-Making Comprehensive Pan-Cancer Tumor Profiling Assays can be Combined with Clinical Informatics Platform with Potential to Reduce Time to Results and Complexity of Clinical Genomic Analysis

• QIAGEN Announces Appointment of New Supervisory Board Member

  1/8/2021

  Dr. Toralf Haag appointed to Supervisory Board and a member of the Audit Committee

• QIAGEN Increases Outlook for 2020 and 2021

  12/8/2020

  Full-year 2020 net sales now expected to grow approximately 22% CER and adjusted EPS to reach $2.13-2.14 CER

• Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)

  11/17/2020

  Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.

• QIAGEN Launches Portable Digital SARS-CoV-2 Antigen Test That Can Accurately Analyze Over 30 Samples Per Hour

  11/11/2020

  QIAreach™ SARS-CoV-2 Antigen Test, developed in partnership with Ellume, is an important step towards decentralized mass screening by processing samples in 2–15 minutes Digital results for dozens of samples per hour and the ability to process antibody tests in parallel, setting new standards in scalability and flexibility Test submitted to FDA for Emergency Use Authorization for US, CE-IVD marking for European Union and other m